A prospective Phase II study to examine the relationship between quality of life and adverse events of first‐line chemotherapy plus cetuximab in patients with KRAS wild‐type unresectable metastatic colorectal cancer: QUACK trial

A prospective trial has not been performed to investigate associations between quality of life (QOL), adverse events (AEs), and overall survival (OS) in the first‐line treatment with cetuximab plus standard chemotherapy for advanced/metastatic colorectal cancer (mCRC). Associations between patient o...

Descripción completa

Detalles Bibliográficos
Autores principales: Iwamoto, Shigeyoshi, Ooki, Akira, Morita, Satoshi, Hara, Hiroki, Tanioka, Hiroaki, Satake, Hironaga, Kataoka, Masato, Kotaka, Masahito, Kagawa, Yoshinori, Nakamura, Masato, Shingai, Tatsushi, Ishikawa, Masashi, Miyake, Yasuhiro, Sudo, Takeshi, Hashiguchi, Yojiro, Yabuno, Taichi, Sakamoto, Junichi, Tsuji, Akihito, Ando, Masahiko, Yamaguchi, Kensei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6144158/
https://www.ncbi.nlm.nih.gov/pubmed/30051609
http://dx.doi.org/10.1002/cam4.1623

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6144158/
https://www.ncbi.nlm.nih.gov/pubmed/30051609
http://dx.doi.org/10.1002/cam4.1623

Ejemplares similares